Literature DB >> 12544522

Cluster randomization trial of sequence mass screening for colorectal cancer.

Shu Zheng1, Kun Chen, Xiyong Liu, Xinyuan Ma, Hai Yu, Kang Chen, Kaiyan Yao, Lun Zhou, Linbo Wang, Peiling Qiu, Yongchuan Deng, Suzhan Zhang.   

Abstract

PURPOSE: Colorectal cancer is a major cause of death worldwide. To reduce the incidence and mortality from rectal cancer, an individual quantitative risk-assessment model (hereafter referred to as the Attributive Degree Value) and reverse passive hemagglutination fecal occult blood test were used in a randomized, controlled, population-based trial that was conducted in Jiashan County, People's Republic of China.
METHODS: All residents of Jiashan County aged 30 years or older were enrolled in the study, and 21 townships in the county were randomized to either a screening (n = 10 townships) or control (n = 11 townships) group. Participants in the screened group submitted a one-article-per-slide stool sample and completed a structured risk-assessment questionnaire from which their attributive degree value was computed. According to study protocol, 4,299 participants were defined as high risk and underwent diagnostic evaluation with 60-cm flexible sigmoidoscopy and, in some cases, an additional screening with colonoscopy.
RESULTS: From 1989 to 1996, cumulative mortality from colon cancer was 90 (95 percent confidence interval, 83-97) per 100,000 in the screened group and 83 (95 percent confidence interval, 76-90) per 100,000 in the control group (log-rank P = 1.49, P = 0.222). Mortality from rectal cancer during this time was 110 (95 percent confidence interval, 102-118) per 100,000 in the screened group, which differed significantly from the control group mortality rate of 161 (95 percent confidence interval, 152-170) per 100,000 (log-rank P = 0.003).
CONCLUSION: Mass screening with a reverse passive hemagglutination fecal occult blood test along with an individual attributive degree value score was effective in reducing mortality from rectal cancer but not in reducing mortality from colon cancer or the incidence of colorectal cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12544522     DOI: 10.1007/s10350-004-6496-2

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  29 in total

Review 1.  Screening for colorectal cancer: established and emerging modalities.

Authors:  Nikhil Pawa; Tan Arulampalam; John D Norton
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-01       Impact factor: 46.802

2.  The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.

Authors:  Chung-Hung Chen; Sheng-Lei Yan; Tsung-Hsun Yang; Shih-Feng Chen; Yung-Hsiang Yeh; Jing-Jim Ou; Chien-Hua Lin; Yueh-Tsung Lee; Chien-Hua Chen
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

3.  Comparative Evaluation of Preliminary Screening Methods for Colorectal Cancer in a Mass Program.

Authors:  Ding Ye; Qiuchi Huang; Qilong Li; Xiyi Jiang; Mayila Mamat; Mengling Tang; Jianbing Wang; Kun Chen
Journal:  Dig Dis Sci       Date:  2017-06-20       Impact factor: 3.199

Review 4.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Barriers to colorectal cancer screening: a case-control study.

Authors:  Shan-Rong Cai; Su-Zhan Zhang; Hong-Hong Zhu; Shu Zheng
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

6.  Barrier-focused intervention to increase colonoscopy attendance among nonadherent high-risk populations.

Authors:  Wen Meng; Xi-Wen Bi; Xiao-Yin Bai; Hua-Feng Pan; Shan-Rong Cai; Qi Zhao; Su-Zhan Zhang
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

7.  Recommendations on screening for colorectal cancer in primary care.

Authors: 
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

8.  Performance value of high risk factors in colorectal cancer screening in China.

Authors:  Wen Meng; Shan-Rong Cai; Lun Zhou; Qi Dong; Shu Zheng; Su-Zhan Zhang
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

9.  Association of a genetic variant in microRNA-146a with risk of colorectal cancer: a population-based case-control study.

Authors:  Yingying Mao; Yingjun Li; Fangyuan Jing; Shaofang Cai; Zhenyu Zhang; Qilong Li; Xinyuan Ma; Jianbing Wang; Mingjuan Jin; Kun Chen
Journal:  Tumour Biol       Date:  2014-04-17

Review 10.  Colorectal cancer screening: 20 years of development and recent progress.

Authors:  Miroslav Zavoral; Stepan Suchanek; Ondrej Majek; Premysl Fric; Petra Minarikova; Marek Minarik; Bohumil Seifert; Ladislav Dusek
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.